Search

Search Constraints

You searched for: Author/Creator Bessette, Paul

Search Results

1. 2022-RA-925-ESGO Development of adjuvant treatment decision support tool for endometrial cancer patients by pooled analysis of data from 2000 women included in the PORTEC-1–3 trials and a prospective cohort study. (20th October 2022)

2. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. (July 2018)

3. A Prospective Single-Arm Study Evaluating the Effects of a Multimodal Physical Therapy Intervention on Psychosexual Outcomes in Women with Dyspareunia After Gynecologic Cancer. Issue 5 (27th April 2021)

4. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Issue 3 (March 2018)

5. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Issue 9 (September 2019)

6. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Issue 9 (September 2019)

7. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. Issue 3 (February 2015)

9. Changes in pelvic floor morphometry and muscle function after multimodal physiotherapy for gynaecological cancer survivors suffering from dyspareunia: a prospective interventional study. (March 2022)

10. Characterizing Pelvic Floor Muscle Function and Morphometry in Survivors of Gynecological Cancer Who Have Dyspareunia: A Comparative Cross-Sectional Study. Issue 4 (30th January 2021)